Ionis Pharmaceuticals - IONS Stock Forecast, Price & News

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares.
View IONS analyst ratings or view top-rated stocks.

9 brokers have issued 12 month target prices for Ionis Pharmaceuticals' stock. Their IONS share price forecasts range from $26.00 to $65.00. On average, they anticipate the company's share price to reach $46.80 in the next twelve months. This suggests a possible upside of 22.5% from the stock's current price.
View analysts price targets for IONS or view top-rated stocks among Wall Street analysts.

Ionis Pharmaceuticals' stock was trading at $30.43 at the start of the year. Since then, IONS shares have increased by 25.5% and is now trading at $38.20.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our IONS earnings forecast.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) posted its earnings results on Wednesday, November, 3rd. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.05. The firm earned $133 million during the quarter, compared to analysts' expectations of $162.01 million. Ionis Pharmaceuticals had a trailing twelve-month return on equity of 1.18% and a net margin of 0.91%. The company's revenue was down 16.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.22) earnings per share.

Ionis Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $594.45 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD).

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

Ionis Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.02%), Bellevue Group AG (6.66%), Price T Rowe Associates Inc. MD (3.38%), ARK Investment Management LLC (2.62%), BVF Inc. IL (2.02%) and Tweedy Browne Co LLC (1.92%). Insiders that own company stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke.
View institutional ownership trends.

Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IONS stock can currently be purchased for approximately $38.20.

Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.43 billion and generates $810 million in revenue each year. The company earns $-28,600,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis.

The company employs 660 workers across the globe.

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700.